Abstract
The mammary gland is a highly hormone-responsive organ, yet research has historically focused almost exclusively on estrogen and progesterone reactivity. The molecular effects of androgen in the breast remain largely unexplored. Transgender men, who are assigned female at birth but identify as male, often undergo gender-affirming androgen therapy to align their physical characteristics with their gender identity. This study presents a single-cell resolution transcriptome, chromatin, and spatial profiling of androgen-treated breasts from transgender men. The findings reveal that male-biased androgen receptor (AR) gene targets are upregulated in AR-expressing cells, while paracrine signaling drives sex-relevant changes in neighboring cell types. Observations include an altered epithelium, shifts in immune populations, and a significant reduction in capillary vasculature. Furthermore, the study identifies a gene regulatory network driving androgen-directed fat loss and metabolic reprogramming. This work provides a high-resolution map of the molecular consequences of androgen in the human breast.
Introduction
While the roles of estrogen and progesterone in breast biology are well-documented, the "other" sex hormone—androgen—has long remained a molecular mystery in this tissue. Understanding androgen signaling is critical for two primary reasons: first, androgen therapy is a cornerstone of gender-affirming care for transgender men; second, the androgen receptor (AR) is increasingly recognized as a potential tumor suppressor in certain breast cancers.
Because murine models possess different hormonal cycles and cell distributions than humans, they serve as poor proxies for studying these effects. To address this gap, researchers analyzed human breast tissue from transgender men, providing a unique window into how testosterone reshapes healthy human tissue at the single-cell level.
Methodology and Data Integration
The researchers employed a "tri-modal" approach to capture a holistic view of the tissue:
- snRNA-seq (Single-nucleus RNA sequencing): Measured gene expression across approximately 105,000 nuclei.
- snATAC-seq (Single-nucleus Assay for Transposase-Accessible Chromatin): Mapped chromatin accessibility to reveal which genomic regions are active.
- CODEX (Co-Detection by Indexing): A spatial proteomics technique used to visualize how molecular changes translate to physical cell-to-cell interactions and tissue structure.
These data were integrated using advanced computational tools, including RNA-velocity to predict cellular trajectories and Gene Regulatory Network (GRN) inference to identify the "master switches" driving tissue transformation. The primary cohort consisted of breast tissue from 9 transgender men (androgen-treated) and 9 cisgender women (controls). Findings were validated against the GTEx (Genotype-Tissue Expression) database to confirm the "male-bias" of the observed changes.
Key Insights: Silencing and Redirection
One of the most striking findings was a global "silencing" effect. Androgen exposure leads to widespread chromatin condensation and a decrease in overall transcriptional and translational output. This suggests that androgen doesn't simply activate "male" genes; it systemically dampens the tissue's previous biological state.
Interestingly, levels of the estrogen receptor (ESR1) remained stable during treatment. However, androgen appears to "redirect" the cellular program by interfering with ESR1 co-regulators, such as JUN. This effectively silences estrogen signaling without removing the receptor itself, demonstrating a sophisticated form of hormonal antagonism.
Paracrine Signaling and Structural Remodeling
Only about 10% of breast epithelial cells express hormone receptors. The study demonstrates that these few cells act as "command centers," utilizing paracrine signaling (secreting factors like AZGP1) to drive changes in neighboring cells that do not sense androgen directly. This ripple effect leads to significant structural changes:
- Vascular Reduction: A significant loss of capillary vasculature was observed, linked to a reduction in PPARG activity and an increase in the anti-angiogenic factor Thrombospondin 1 (THBS1).
- Epithelial Remodeling: Basal cells lost markers essential for lactation and contraction, such as the oxytocin receptor (OXTR) and ACTA2.
- Immune Shifts: The local immune microenvironment shifted; remodeling-associated macrophages decreased, while CD4+ T-cells increased and migrated closer to epithelial structures.
Metabolic Reprogramming and Fat Loss
The breast tissue shifted toward a male-like metabolic profile. The authors identified a specific gene regulatory network involving TCF7L2 and NR4A1 that constrains fat regeneration and promotes lipid degradation. This provides a molecular explanation for the reduction in breast tissue volume often observed during androgen therapy.
Discussion and Clinical Implications
The study’s findings on global chromatin silencing and reduced angiogenesis suggest a potential mechanism for cancer protection. These conditions are generally hostile to tumor growth and nutrient supply, which may explain why androgen-treated tissue is associated with a lower risk of certain malignancies.
While the study is limited by a relatively small sample size (n=18) and the lack of systemic hormone level data for all controls, it provides a vital roadmap. Future work using ChIP-seq will be necessary to physically map the binding events of AR and ESR1 co-regulators. Ultimately, this research offers new leads for using androgen-related pathways in both gender-affirming care and breast cancer prevention.
Summary updated